Literature DB >> 8101371

Predictors of response to neuroleptic treatment in schizophrenia.

R G Stern1, R S Kahn, M Davidson.   

Abstract

Baseline symptom severity, early reduction in symptom severity, initial subjective response to neuroleptic treatment, the degree of brain atrophy, and early changes in pHVA levels appear to predict treatment outcome in schizophrenic patients. Computerized EEG results, neuropsychological and neurophysiologic tests, and baseline pHVA concentrations require further examination. Only a limited proportion of variance in treatment response, however, could be explained by either of the nine predictors alone or combined. Therefore, further research is necessary to discover yet unidentified determinants of treatment response. Future studies should test the validity and reliability of these five promising predictors in large groups of male and female patients, employ high standards for assessment reliability of clinical parameters, and use absolute rating scores on psychopathology as well as functional scales for the definition of good and poor treatment response. Furthermore, the statistical approach for data analysis should take in consideration the need for appropriate corrections when multiple correlations are performed and should test the extent to which these predictors are interdependent.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8101371

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN: 0193-953X


  7 in total

1.  The long-term effects of placebo in patients with chronic schizophrenia.

Authors:  R J Wyatt; I D Henter; J J Bartko
Journal:  Biol Psychiatry       Date:  1999-10-15       Impact factor: 13.382

2.  How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials.

Authors:  Myrto T Samara; Adriani Nikolakopoulou; Georgia Salanti; Stefan Leucht
Journal:  Schizophr Bull       Date:  2019-04-25       Impact factor: 9.306

Review 3.  Basal ganglia pathology in schizophrenia: dopamine connections and anomalies.

Authors:  Emma Perez-Costas; Miguel Melendez-Ferro; Rosalinda C Roberts
Journal:  J Neurochem       Date:  2010-01-20       Impact factor: 5.372

4.  Treatment of the special patient with schizophrenia.

Authors:  R R Conley; D L Kelly
Journal:  Dialogues Clin Neurosci       Date:  2001-06       Impact factor: 5.986

5.  Treatment-refractory schizophrenia.

Authors:  Asaf Caspi; Michael Davidson; Carol A Tamminga
Journal:  Dialogues Clin Neurosci       Date:  2004-03       Impact factor: 5.986

6.  Genome-wide association study of treatment refractory schizophrenia in Han Chinese.

Authors:  Ying-Jay Liou; Hui-Hung Wang; Ming-Ta Michael Lee; Sheng-Chang Wang; Hung-Lun Chiang; Cheng-Chung Chen; Ching-Hua Lin; Ming-Shun Chung; Chien-Cheng Kuo; Ding-Lieh Liao; Ching-Kuan Wu; Chih-Min Liu; Yu-Li Liu; Hai-Gwo Hwu; I-Ching Lai; Shih-Jen Tsai; Chia-Hsiang Chen; Hui-Fen Liu; Yi-Chun Chou; Chien-Hsiun Chen; Yuan-Tsong Chen; Chen-Jee Hong; Jer-Yuarn Wu
Journal:  PLoS One       Date:  2012-03-27       Impact factor: 3.240

7.  Influencing Factors and Predictors of Early Response in Schizophrenia Patients Receiving the Paliperidone Extended-Release Tablets (Paliperidone ER).

Authors:  Seung-Ho Jung; Jin-Sang Yoon; Yong-Min Ahn; Yong-Sik Kim; Chul-Eung Kim
Journal:  Psychiatry Investig       Date:  2013-12-16       Impact factor: 2.505

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.